tetano
Editor, Senior Moderator
Drug Discov Today
. 2021 Jul 28;S1359-6446(21)00331-7.
doi: 10.1016/j.drudis.2021.07.021. Online ahead of print.
Intranasal vaccines for SARS-CoV-2: from challenges to potential in COVID-19 management
Vivek P Chavda[SUP] 1 [/SUP], Lalitkumar K Vora[SUP] 2 [/SUP], Anjali K Pandya[SUP] 3 [/SUP], Vandana B Patravale[SUP] 3 [/SUP]
Affiliations
Abstract
Unlike conventional Coronavirus 2019 (COVID-19) vaccines, intranasal vaccines display a superior advantage because the nasal mucosa is often the initial site of infection. Preclinical and clinical studies concerning intranasal immunisation elicit high neutralizing antibody generation and mucosal IgA and T cell responses that avoid severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in both the upper and lower respiratory tract. A nasal formulation is non-invasive with high appeal to patients. Intranasal vaccines enable self-administration and can be designed to survive at ambient temperatures, thereby simplifying logistical aspects of transport and storage. In this review, we provide an overview of nasal vaccines with a focus on formulation development as well as ongoing preclinical and clinical studies for SARS-CoV-2 intranasal vaccine products.
Keywords: COVID-19; SARS-CoV-2; antigen-presenting cells (APCs); dendritic cells; nasal spray; nasal vaccine.
. 2021 Jul 28;S1359-6446(21)00331-7.
doi: 10.1016/j.drudis.2021.07.021. Online ahead of print.
Intranasal vaccines for SARS-CoV-2: from challenges to potential in COVID-19 management
Vivek P Chavda[SUP] 1 [/SUP], Lalitkumar K Vora[SUP] 2 [/SUP], Anjali K Pandya[SUP] 3 [/SUP], Vandana B Patravale[SUP] 3 [/SUP]
Affiliations
- PMID: 34332100
- DOI: 10.1016/j.drudis.2021.07.021
Abstract
Unlike conventional Coronavirus 2019 (COVID-19) vaccines, intranasal vaccines display a superior advantage because the nasal mucosa is often the initial site of infection. Preclinical and clinical studies concerning intranasal immunisation elicit high neutralizing antibody generation and mucosal IgA and T cell responses that avoid severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in both the upper and lower respiratory tract. A nasal formulation is non-invasive with high appeal to patients. Intranasal vaccines enable self-administration and can be designed to survive at ambient temperatures, thereby simplifying logistical aspects of transport and storage. In this review, we provide an overview of nasal vaccines with a focus on formulation development as well as ongoing preclinical and clinical studies for SARS-CoV-2 intranasal vaccine products.
Keywords: COVID-19; SARS-CoV-2; antigen-presenting cells (APCs); dendritic cells; nasal spray; nasal vaccine.